164 related articles for article (PubMed ID: 23135345)
1. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis.
Yamamoto T; Tsujimoto M; Hamaya E; Sowa H
J Bone Miner Metab; 2013 Mar; 31(2):199-205. PubMed ID: 23135345
[TBL] [Abstract][Full Text] [Related]
2. Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases.
Miyauchi A; Matsumoto T; Sugimoto T; Tsujimoto M; Warner MR; Nakamura T
Bone; 2010 Sep; 47(3):493-502. PubMed ID: 20580870
[TBL] [Abstract][Full Text] [Related]
3. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
Eastell R; Mitlak BH; Wang Y; Hu M; Fitzpatrick LA; Black DM
Osteoporos Int; 2019 Mar; 30(3):667-673. PubMed ID: 30635696
[TBL] [Abstract][Full Text] [Related]
4. PINP as an aid for monitoring patients treated with teriparatide.
Tsujimoto M; Chen P; Miyauchi A; Sowa H; Krege JH
Bone; 2011 Apr; 48(4):798-803. PubMed ID: 21168536
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2016 May; 27(5):1869-74. PubMed ID: 26759334
[TBL] [Abstract][Full Text] [Related]
6. Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels.
Takada J; Yoshimura T; Uzawa T
J Bone Miner Metab; 2021 May; 39(3):484-493. PubMed ID: 33389132
[TBL] [Abstract][Full Text] [Related]
7. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
[TBL] [Abstract][Full Text] [Related]
8. Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study.
Miyauchi A; Matsumoto T; Shigeta H; Tsujimoto M; Thiebaud D; Nakamura T
J Bone Miner Metab; 2008; 26(6):624-34. PubMed ID: 18979163
[TBL] [Abstract][Full Text] [Related]
9. Skeletal response to treatment with teriparatide (TPD) after bisphosphonate in post-menopausal women with osteoporosis and a high prevalence of secondary risk factors in real-life setting of a metabolic bone clinic; effect of age and vitamin D status.
Mok J; Brown C; Moore AEB; Min SS; Hampson G
Endocr Res; 2018 Aug; 43(3):195-202. PubMed ID: 29652557
[TBL] [Abstract][Full Text] [Related]
10. Analysis of daily teriparatide treatment for osteoporosis in men.
Niimi R; Kono T; Nishihara A; Hasegawa M; Matsumine A; Kono T; Sudo A
Osteoporos Int; 2015 Apr; 26(4):1303-9. PubMed ID: 25567777
[TBL] [Abstract][Full Text] [Related]
11. Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.
Sugimoto T; Nakamura T; Nakamura Y; Isogai Y; Shiraki M
Osteoporos Int; 2014 Mar; 25(3):1173-80. PubMed ID: 24108429
[TBL] [Abstract][Full Text] [Related]
12. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
Michalska D; Luchavova M; Zikan V; Raska I; Kubena AA; Stepan JJ
Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
[TBL] [Abstract][Full Text] [Related]
13. Relationship between bone turnover and density with teriparatide, denosumab or both in women in the DATA study.
Tsai JN; Burnett-Bowie SM; Lee H; Leder BZ
Bone; 2017 Feb; 95():20-25. PubMed ID: 27840301
[TBL] [Abstract][Full Text] [Related]
14. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial.
Saag KG; Zanchetta JR; Devogelaer JP; Adler RA; Eastell R; See K; Krege JH; Krohn K; Warner MR
Arthritis Rheum; 2009 Nov; 60(11):3346-55. PubMed ID: 19877063
[TBL] [Abstract][Full Text] [Related]
15. A retrospective analysis of nonresponse to daily teriparatide treatment.
Niimi R; Kono T; Nishihara A; Hasegawa M; Kono T; Sudo A
Osteoporos Int; 2016 Sep; 27(9):2845-2853. PubMed ID: 27055464
[TBL] [Abstract][Full Text] [Related]
16. Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial.
Takada J; Dinavahi R; Miyauchi A; Hamaya E; Hirama T; Libanati C; Nakamura Y; Milmont CE; Grauer A
J Bone Miner Metab; 2020 May; 38(3):310-315. PubMed ID: 31707465
[TBL] [Abstract][Full Text] [Related]
17. ANABOLIC BONE WINDOW WITH WEEKLY TERIPARATIDE THERAPY IN POSTMENOPAUSAL OSTEOPOROSIS: A PILOT STUDY.
Gopalaswamy V; Dhibar DP; Gupta V; Arya AK; Khandelwal N; Bhansali A; Garg SK; Agarwal N; Rao SD; Bhadada SK
Endocr Pract; 2017 Jun; 23(6):657-661. PubMed ID: 28225309
[TBL] [Abstract][Full Text] [Related]
18. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
19. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
Blumsohn A; Marin F; Nickelsen T; Brixen K; Sigurdsson G; González de la Vera J; Boonen S; Liu-Léage S; Barker C; Eastell R;
Osteoporos Int; 2011 Jun; 22(6):1935-46. PubMed ID: 20938767
[TBL] [Abstract][Full Text] [Related]
20. A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study.
Kung AW; Pasion EG; Sofiyan M; Lau EM; Tay BK; Lam KS; Wilawan K; Ongphiphadhanakul B; Thiebaud D
Curr Med Res Opin; 2006 May; 22(5):929-37. PubMed ID: 16709314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
